- Home
- SF vs PCVX Comparison
SF vs PCVX Comparison
Compare SF & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SF
- PCVX
- Stock Information
- Founded
- SF 1890
- PCVX 2013
- Country
- SF United States
- PCVX United States
- Employees
- SF N/A
- PCVX N/A
- Industry
- SF Investment Bankers/Brokers/Service
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- SF Finance
- PCVX Health Care
- Exchange
- SF Nasdaq
- PCVX Nasdaq
- Market Cap
- SF 11.4B
- PCVX 4.0B
- IPO Year
- SF N/A
- PCVX 2020
- Fundamental
- Price
- SF $112.46
- PCVX $42.45
- Analyst Decision
- SF Buy
- PCVX Strong Buy
- Analyst Count
- SF 8
- PCVX 8
- Target Price
- SF $122.75
- PCVX $114.17
- AVG Volume (30 Days)
- SF 741.2K
- PCVX 1.9M
- Earning Date
- SF 10-22-2025
- PCVX 11-05-2025
- Dividend Yield
- SF 1.64%
- PCVX N/A
- EPS Growth
- SF 9.88
- PCVX N/A
- EPS
- SF 5.17
- PCVX N/A
- Revenue
- SF $5,091,577,000.00
- PCVX N/A
- Revenue This Year
- SF $10.46
- PCVX N/A
- Revenue Next Year
- SF $12.28
- PCVX N/A
- P/E Ratio
- SF $21.73
- PCVX N/A
- Revenue Growth
- SF 11.86
- PCVX N/A
- 52 Week Low
- SF $73.27
- PCVX $27.66
- 52 Week High
- SF $120.64
- PCVX $116.00
- Technical
- Relative Strength Index (RSI)
- SF 51.48
- PCVX 62.99
- Support Level
- SF $107.18
- PCVX $42.00
- Resistance Level
- SF $113.15
- PCVX $45.12
- Average True Range (ATR)
- SF 2.79
- PCVX 2.01
- MACD
- SF 0.10
- PCVX -0.05
- Stochastic Oscillator
- SF 72.13
- PCVX 62.78
About SF Stifel Financial Corporation
Stifel Financial Corp is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 67% of the company's net revenue is derived from its world-wide wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.